SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

September 23, 2013 07:00 ET

Implant Sciences Continues to Attract Top Talent as It Adds Industry Veteran to Sales Team

Talented ETD Veteran With Strong Track Record Building Business Hired as Sales Director for Latin America

WILMINGTON, MA--(Marketwired - Sep 23, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today the appointment of Hector Giraldo as Sales Director for Latin America. Mr. Giraldo has over 15 years of experience in growing sales in Latin America with security industry companies including Morpho, Smiths Detection, and Rapiscan. 

Mr. Giraldo, who is fluent in both Spanish and Portuguese, was most recently Vice President, International Business Development at The Provectus Group, a provider of integrated security solutions for international public safety. Prior, he was Director of Sales and Business Development at Morpho, formerly L-1, where he concentrated on the development of sales and projects with international governments. As Director for Latin America at Rapiscan Systems, Mr. Giraldo oversaw the complete distribution of more than 30 products in 21 countries. He directly managed hiring and training of internal team members, and external channel partners. Prior to joining Rapiscan, Mr. Giraldo was International Sales Manager at Smiths Detection where he was responsible for complete market development in Latin America and the Caribbean, doubling sales in the first year, with over 30% increases in sales in subsequent years. Early in his career, while serving as Technical Sales Representative at Scintrex Analytical & Security, Mr. Giraldo launched a new product family and grew revenues fourfold in the region. He is also a speaker and seminar leader on counter-terrorism technologies and explosives and chemical weapons detection.

"Hector has gained his in-depth industry experience with some of the largest companies in the security equipment business. He's proven his ability to build sales and distribution networks in Latin America that have directly resulted in significant revenue increases," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "We're proud of Implant Sciences' reputation in the industry, not only for our high-performance next-generation explosives and drugs trace detection equipment, but also for being a company where the best and brightest in our industry are choosing to work. We welcome Hector to our team and look forward to increasing our sales in Latin America."

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by March 31, 2014; if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; we continue to incur substantial operating losses and may never be profitable; our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern; our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risk that our business is subject to intense competition; the risks that our markets are subject to rapid technology change and that our success depends on our ability to develop and introduce new products; the risks that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others: and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

For further information, you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended June 30, 2012. The Company assumes no obligation to update the information contained in this press release.

Contact Information

  • Contact:

    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact